Qilu Pharmaceutical's Class-1 Innovation Drug Sparks the RMB 160 Billion Anti-Tumor Market
May 22, 2026 16:25
CST Updated
18:26
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer